TY  - GEN
AB  - In 2020, over 26.8 million people around the world were affected by opioid use disorder, with approximately 2.7 million cases of opioid use disorder in the United States alone. Since the beginning of the COVID-19 pandemic, rates of fentanyl use and opioid related overdoses nearly doubling. Effective medications for opioid use disorder (MOUD) have been well studied and have been shown to reduce opioid cravings, to reduce opioid use and to prevent opioid related deaths. Despite the availabilities of these MOUD, the medications are largely underutilized. Much of this lack is due to the many barriers to initiating MOUD treatment, including stigma, access to care, perception of strict oversight, and comorbid mental health issues. Shared decision making (SDM) in clinical practice involves making choices about a treatment plan through partnership between the clinician(s) and the patient. Decision-making tools can help encourage and guide SDM conversation. SDM has been found in initial studies to increase likelihood of MOUD induction. Despite these reports, only an estimated 23% of MOUD clinics invite patients into decision making processes. There are currently no validated SDM tools available to the public directed towards patients for MOUD initiation. Our study aimed to create a SDM tool for MOUD and to evaluate the feasibility and accessibility of this tool to patients and providers.
AD  - Oregon Health and Science University
AU  - David, Rachel
DA  - 2023
DO  - 10.6083/4q77fs17f
DO  - DOI
ED  - Cahen, Viviane
ED  - Chan, Brian L.
ED  - Co-PI
ED  - Co-PI
ID  - 10073
KW  - Opioid-Related Disorders
KW  - Health Services Accessibility
KW  - Fentanyl
KW  - Opiate Overdose
KW  - Decision Making, Shared
L1  - https://digitalcollections.ohsu.edu/record/10073/files/David.Rachel.2023.pdf
L2  - https://digitalcollections.ohsu.edu/record/10073/files/David.Rachel.2023.pdf
L4  - https://digitalcollections.ohsu.edu/record/10073/files/David.Rachel.2023.pdf
LK  - https://digitalcollections.ohsu.edu/record/10073/files/David.Rachel.2023.pdf
N2  - In 2020, over 26.8 million people around the world were affected by opioid use disorder, with approximately 2.7 million cases of opioid use disorder in the United States alone. Since the beginning of the COVID-19 pandemic, rates of fentanyl use and opioid related overdoses nearly doubling. Effective medications for opioid use disorder (MOUD) have been well studied and have been shown to reduce opioid cravings, to reduce opioid use and to prevent opioid related deaths. Despite the availabilities of these MOUD, the medications are largely underutilized. Much of this lack is due to the many barriers to initiating MOUD treatment, including stigma, access to care, perception of strict oversight, and comorbid mental health issues. Shared decision making (SDM) in clinical practice involves making choices about a treatment plan through partnership between the clinician(s) and the patient. Decision-making tools can help encourage and guide SDM conversation. SDM has been found in initial studies to increase likelihood of MOUD induction. Despite these reports, only an estimated 23% of MOUD clinics invite patients into decision making processes. There are currently no validated SDM tools available to the public directed towards patients for MOUD initiation. Our study aimed to create a SDM tool for MOUD and to evaluate the feasibility and accessibility of this tool to patients and providers.
PB  - Oregon Health and Science University
PY  - 2023
T1  - Acceptability and feasibility of a shared decision-making tool for medication for opioid use disorder
TI  - Acceptability and feasibility of a shared decision-making tool for medication for opioid use disorder
UR  - https://digitalcollections.ohsu.edu/record/10073/files/David.Rachel.2023.pdf
Y1  - 2023
ER  -